



## Review Article

# A systematic review on genome-wide association studies exploring comorbidity in bipolar disorder

Selena Aranda<sup>a</sup>, Esther Jiménez<sup>b</sup>, Lourdes Martorell<sup>a</sup>, Gerard Muntané<sup>a,c</sup>, Eduard Vieta<sup>b</sup>, Elisabet Vilella<sup>a,\*</sup>

<sup>a</sup> Hospital Universitari Institut Pere Mata, Institut d'Investigació Sanitària Pere Virgili (IISPV), Universitat Rovira Virgili (URV), Centro de investigación biomédica en red en Salud Mental (CIBERSAM). Reus, Catalonia, Spain

<sup>b</sup> Bipolar and Depressive Disorders Unit, Hospital Clinic, Institute of Neurosciences, University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de investigación biomédica en red en Salud Mental (CIBERSAM). Barcelona, Catalonia, Spain

<sup>c</sup> Institute of Evolutionary Biology (IBE), Spanish National Research Council (CSIC), Universitat Pompeu Fabra (UPF), Barcelona, Catalonia, Spain



## ARTICLE INFO

## Key words:

Bipolar disorder  
Comorbidity  
Endophenotype  
Single nucleotide polymorphism  
Genome-wide association study

## ABSTRACT

**Background:** The comorbidities associated with bipolar disorder (BD) can worsen patients' prognosis and increase economic costs to society. Currently, efforts are being made to identify new endophenotypes characterized by the presence of BD and another concomitant condition.

**Methods:** We performed a search on PubMed and GWAS catalog databases to find genome-wide association studies carried out on patients with BD with any other comorbid condition. We extracted the associated SNPs that attained statistical significance and listed them to appraise their potential to define new BD endophenotypes based on the presence of comorbidities.

**Results:** Six articles fulfilled the inclusion criteria, and all included only patients with BD type-I (BDI). The identified comorbid conditions were migraine, externalizing disorders and eating disorders. BDI with comorbid migraine was associated with rs1160720 in the *NBEA* gene. BDI with comorbid anorexia or bulimia nervosa was associated with rs4854912 and rs13100379 in the *SOX2-OT* gene. BDI with comorbid substance abuse was associated with rs1039002 in the *PDE10A* gene, rs12563333 upstream of the *MARK1* gene, and rs13220542 downstream of the *MAP3K7* gene. BDI with comorbid alcohol dependence and substance abuse was associated with rs2727943, which is located between *CNTN4* and *CNTN6*. However, such associations were not strong enough to replicate.

**Limitations:** The main limitations are the small size and poor description of the samples used in the included articles.

**Conclusions:** Some genes involved in neurotransmission, stress response, neurogenesis and synaptic plasticity may be associated with comorbid BDI. However, evidence is too weak to consider new endophenotypes in BDI.

## 1. Introduction

Bipolar disorder (BD) is a group of chronic, severe and heterogenic psychiatric disorders characterized by the presence of mood swings that range from depressive to manic phases. This diagnosis includes two subtypes: bipolar disorder I (BDI), which is characterized by the presence

of at least one manic episode, and bipolar disorder II (BDII), where the presence of at least one hypomanic and one major disorder episode are required for its diagnosis (Carvalho et al., 2020; Grande et al., 2016). BD is a highly heritable condition with genetic contributions explaining approximately 80% of its variability (Gordovez and McMahon, 2020). In addition, environmental factors play a critical role (Aldinger and

**Abbreviations:** BD, Bipolar Disorder; BDI, Bipolar Disorder type I; BDII, Bipolar Disorder type II; BiGS, Bipolar Genetics Study; CBD, Comorbid Bipolar Disorder; CBBDI, Comorbid Bipolar Disorder type I; CNTN4, Contactin-4; CNTN6, Contactin-6; DIGS, Diagnostic Interview for Genetic Studies; DSM-X-R, Diagnostic and Statistical Manual of Mental Disorder Version X Revised; GABA, Gamma aminobutyric acid; GAIN, Genetic Association Information Network; GWAS, Genome-wide association study; ICD-DCR, Schizophrenia and Affective Disorders Schedule – Lifetime version (SADS-L) and diagnosed according to ICD-10 diagnostic criteria; MAP3K7, Mitogen-Activated Protein Kinase Kinase Kinase 7; MARK1, MAP/Microtubule Affinity-Regulating Kinase 1; NBEA, Neurobeachin; NHS, National Health Service; RDC, Research Diagnostic Criteria; PDE10A, Phosphodiesterase 10A; SABP, Schizo-Affective Bipolar Disorder; SNP, Single nucleotide polymorphism; SOX2-OT, SRY-Box Transcription Factor 2 Overlapping Transcript; UCL, University College of London.

\* Corresponding author.

E-mail address: [vilellae@peremata.com](mailto:vilellae@peremata.com) (E. Vilella).

<https://doi.org/10.1016/j.jadr.2021.100130>

Received 23 December 2020; Received in revised form 15 February 2021; Accepted 16 March 2021

Available online 18 March 2021

2666-9153/© 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>)

Schulze, 2017). A recent genome-wide association study (GWAS) in a large sample identified common variants located in 30 genes that explain about 25% of its heritability. Findings from the same study indicate the existence of an extensive polygenic architecture of this psychiatric condition, suggesting that BDI is more genetically correlated with schizophrenia, whereas BDII is more strongly correlated to major depression disorder (McIntyre et al., 2020; Stahl et al., 2019). Classic linkage and candidate genes studies identified genes associated with BD but with little consistency (Gordovez and McMahon, 2020).

BD could be highly disruptive and negatively impacts on occupational status, social, and family functioning. In this sense, a considerable proportion of adult patients cannot perform their jobs (Judd et al., 2008) and may present cognitive impairment (Samamé, 2013; Solé et al., 2016). With regards to pediatric and adolescent patients, BD also negatively affects their social, academic and family functioning (Wagner and Dineen Wagner, 2004).

In addition, the course of the illness may be worsened by the high frequency of comorbidities, which is defined as the presence of a concurrent disease in addition to the main BD diagnosis. A considerable economic burden is associated with bipolar disorder (Cloutier et al., 2018; Ferrari et al., 2016), and this burden substantially increases with the presence of any other comorbid condition (Hirschfeld and Vornik, 2005; McElroy, 2004). The percentage of psychiatric comorbidities in BD has been reported as 31% of cases (Vieta et al., 2001). However, when considering any condition, the percentage of comorbidity increases to 96.3% (Sylvia et al., 2015). In this sense, presence of comorbidity in patients with BD is associated with an earlier onset, lower remission rates, increased number of depressive episodes and a greater risk of suicidal behavior (Goes, 2015; Popovic et al., 2015; Vieta et al., 2001). In addition, comorbid conditions may also interfere with an accurate diagnosis, hampering treatment prescription and therefore reducing life expectancy (Chang et al., 2011; Crump et al., 2013; McIntyre et al., 2008, 2004; Popovic et al., 2015; Sylvia et al., 2015).

Comorbidities in BD have been proposed to be potential indicators of distinct subtypes of BD (Potash et al., 2007). Therefore, efforts are being made to identify more homogeneous groups of comorbid bipolar disorder (CBD) patients' phenotypes that may help to ensure a more accurate diagnosis and facilitate the design of more tailored subtype-based treatments. In this regard, genetic studies are useful to identify the genetic overlap associated with comorbid conditions that may define new endophenotypes.

With the goal of better understanding the genetics underlying subgroups of patients with BD presenting with any other comorbid diagnosis, we conducted this systematic review 1) to review GWAS performed on patients with BD presenting any other comorbidity, 2) to identify those genes associated with the aforementioned group of patients, and 3) to evaluate their potential to define new endophenotypes of BD.

## 2. Methods

This systematic review was performed following the PRISMA guidelines (Liberati et al., 2009; Moher et al., 2009).

### 2.1. Study selection and data extraction

We performed a PubMed search (<https://www.ncbi.nlm.nih.gov/pubmed/>) on June 23, 2020. The text ((GWAS) OR (Genome-wide association study)) AND (comorb\*) AND (bipolar disorder) was used as a search string. Additionally, on the same date, we searched the term "bipolar" in the GWAS Catalog (<https://www.ebi.ac.uk/gwas/>). No language, publication date or other restrictions were imposed in any of the searches.

The following inclusion criterion was selected with the aim of identifying relevant and homogenous studies: GWAS with a sample recruited exclusively with the inclusion criteria of comorbid bipolar disorder (CBD) (i.e., patients simultaneously suffering from BD and any other

condition) independently of sample size, population background, age or sex. Exclusion criteria were as follows: (a) duplicate publications; (b) studies without GWAS data; (c) reviews, case reports, meeting reports, meta-analysis and conference abstracts; (d) linkage or candidate gene studies; (e) studies mainly investigating treatment outcome or drug-induced side effects; (f) GWAS assessing only BD without comorbidity; (g) studies based on genome-wide data assessing the genetic overlap between BD and other diagnostics; and (h) studies performed on schizoaffective bipolar disorder.

Eligibility assessment was performed by the first author and revised by all co-authors. Titles and abstracts of the retrieved studies were roughly screened and excluded if the content was not relevant for the purpose of the systematic review. The remaining articles were thoroughly examined and excluded if the methodology or design did not meet the eligibility criteria.

Finally, the following data were extracted into a table by the first author and checked by all the co-authors: sample size, phenotypes, study design, and most statistically significant single nucleotide polymorphisms (SNPs) with their P-values.

### 2.2. Summary measures and risk of bias

P-values approximating the consensual statistical significance (i.e.,  $P < 5 \times 10^{-8}$ ) were the primary measure of SNP association to CBD. However, to ascertain the validity of the results, size and homogeneity of the samples were also taken into consideration. Additionally, to reduce the bias from duplicate sample, we agreed to exclude all GWAS findings from replication analysis with discovery-sample overlap. We also were in agreement with exclusion of confirmation results in case of overlap with the discovery sample.

## 3. Results


### 3.1. Study selection and data extraction

PubMed and GWAS catalog databases provided 131 citations. After removal of duplicates, 119 remained. Following review of the abstracts, 99 articles were excluded because no sign of assessment of comorbidity in BD appeared, and 21 full-text articles were assessed for eligibility. Of those, 15 reports were discarded as these reports employed methodology other than GWAS. Eventually, 6 publications were identified for inclusion in the review. Fig. 1 depicts the flow-chart of the study selection process.

The characteristics of included studies are summarized in Table 1.

Of note, all included articles used a sample of patients with comorbid bipolar disorder type-I (referred as CBDI hereafter), and no study on comorbid bipolar disorder type-II patients was found. The identified comorbid conditions included one neurological disorder, i.e., migraine (Jacobsen et al., 2015), and two psychiatric disorders, i.e., eating disorders (Liu et al., 2016; Winham et al., 2014) and externalizing disorders (Kerner et al., 2011; Lydall et al., 2011; Swaminathan et al., 2015). The GWAS design varied among the studies, ranging from comorbid case-control, where cases were CBDI and controls were BDI without comorbidity, to case-only, where CBDI and BDI patients were compared, and case-control, where cases were BDI patients and controls were healthy individuals (Table 1). Regrettably, none of the studies were conducted separately in both sexes to assess whether gender differences influenced the results.

It is worth mentioning that one study also included a meta-analysis (Winham et al., 2014), and the suggestive associations were also taken into consideration. Furthermore, Kerner and colleagues evaluated a specific subgroup of patients with BDI who presented psychotic symptoms (Kerner et al., 2007).



**Fig. 1.** Flow-chart of the study selection process.

**Table 1**  
Material and methods of the selected articles.

Comorbid diagnosis	Study reference	Study design	Discovery sample	Replication sample	Diagnosis	Diagnostic procedure for BD	Diagnostic procedure for the comorbid condition in the discovery sample	Diagnostic procedure for the comorbid condition in the replication sample
Migraine	Jacobsen et al. J Affect Disord. 2015	Case-only	BiGS	GAIN + BiGS	BDI	DIGS	Self-reported	Self-reported
Eating disorders	Winham et al. J Affect Disord. 2014	Case-control Comorbid case-control	GAIN	Mayo Clinic Biobanks	BDI	DIGS, DSM-IV	Yes/No questionnaire	Clinical diagnostic
	Liu et al. J Affect Disord. 2016	Case-control Comorbid case-control Case-only	BiGS	–	BDI	DIGS, DSM-III-R, DSM-IV	Clinical diagnostic	–
Externalizing disorders	Swaminathan et al. J Affect Disord. 2015	Case-control Comorbid case-control Case-only	BiGS	–	BDI	DIGS	Clinical diagnostic	–
	Kerner et al. PLoS One, 2011	Comorbid case-control	GAIN	–	BDI	DSM-III-R, DSM-IV-R	Clinical diagnostic	–
	Lydall et al. Psychiatr Genet. 2011	Case-control Comorbid case-control	UCL + NHS	–	BDI	ICD-DCR, RDC, DSM-III-R	Clinical diagnostic	–

Summary of the characteristics of the included articles, stratified by comorbidity. BDI: Bipolar disorder type-I. BiGS: Bipolar Genetics Study. DIGS: Diagnostic Interview for Genetic Studies. DSM-III: Diagnostic and Statistical Manual of Mental Disorder Version III. DSM-III-R: Diagnostic and Statistical Manual of Mental Disorder Version III Revised. DSM-IV: Diagnostic and Statistical Manual of Mental Disorder Version IV. DSM-IV-R: Diagnostic and Statistical Manual of Mental Disorder Version IV Revised. GAIN: Genetic Association Information Network. ICD-DCR: Schizophrenia and Affective Disorders Schedule – Lifetime version (SADS-L) and diagnosed according to ICD-10 diagnostic criteria. NHS: National Health Service. RDC: Research Diagnostic Criteria. UCL: University College of London.

### 3.2. Summary measurements and risk of bias

SNPs approximating the consensual genomic statistical significance ( $P < 5 \times 10^{-8}$ ) are summarized in Table 2. We also listed all suggestive SNPs ( $P < 10 \times 10^{-5}$ ) in Supplementary Table 1. To facilitate comprehension, each study is contextualized in terms of comorbidity.

The validity of the results across all studies may be biased due to their small sample size. Additionally, the heterogeneous pool of patients with externalizing disorders and eating disorders may also interfere with the quality of the studies.

### 3.3. Description and main results of the included studies on the systematic review according to comorbidity

#### 3.3.1. BDI with comorbid migraine

To date, only one case-only GWAS comparing BDI patients with and without a migraine diagnosis has been performed (Jacobsen et al., 2015), and one SNPs achieved the statistical significance threshold in the discovery sample. The SNP rs1160720 ( $P = 2.97 \times 10^{-8}$ ) is located in the Neurobeachin (NBEA) gene, and several other neighboring SNPs in linkage disequilibrium with rs1160720 showed a trend for association

**Table 2**

Summary of the most significant SNP variants associated with comorbid diagnosis in patients with BD based on GWAS data.

Comorbidity	Reference	Study	Discovery sample size (CBD/BD/control)	Replication sample size (CBD/BD/control)	Chr	Base pair (GRCh38)	SNP	Gene	P-value	
Migraine	Jacobsen et al. J Affect Disord. 2015	Case-only	460/914/-	289/697/-	13	35,312,538	rs1160720	NBEA	$3.0 \times 10^{-8}$	
Eating disorders	Liu et al. J Affect Disord. 2016	Comorbid case-control	184-/1370	-	3	181,063,312	rs4854912	SOX2-OT	$8.9 \times 10^{-8}$	
					3		rs13100379	SOX2-OT	$9.7 \times 10^{-8}$	
Externalizing disorders	Kerner et al. PLoS One. 2011	Comorbid case-control (1)	283-/1034	-	6	165,741,969	rs1039002	PDE10A	$1.7 \times 10^{-8}$	
					1		rs12563333	MARK1	$5.9 \times 10^{-8}$	
		Comorbid case-control (2)	246-/1034	-	6	220,484,892	90,909,043	rs13220542	MAP3K7	$9.0 \times 10^{-8}$
					3	1,856,289	rs2727943	CNTN4/CNTN6	$3.3 \times 10^{-8}$	

a. P-value obtained by Fisher exact test was considerably weaker ( $4.2 \times 10^{-7}$  for rs11031481,  $1.4 \times 10^{-5}$  for rs9566845 and  $1.5 \times 10^{-5}$  for rs9566845).

b. SNP associated in the case-only meta-analysis where GAIN and Mayo samples were combined.

c. SNP associated in the CBD case-control meta-analysis where GAIN and Mayo samples were combined.

d. SNP associated in the case-only meta-analysis where discovery and replication GAIN samples were combined.

e. This replication sample consisted in 133 migrainous and 333 nonmigrainous individuals with attention deficit hyperactivity disorder (ADHD).

( $P < 5 \times 10^{-5}$ , Table S1). However, the association of rs1160720 was not validated in the replication sample.

### 3.3.2. BDI with comorbid eating disorders

We found one study performed in BDI patients with binge eating disorder (Winham et al., 2014) and another study performed in patients with anorexia nervosa or bulimia nervosa (Liu et al., 2016). The first study included case-only, case-control and comorbid case-control GWAS as well as a meta-analysis and a replication sample (Winham et al., 2014). However, no SNP reached statistical significance. The second study included case-control, comorbid case-control and case-only GWAS. In this study, two SNPs almost attaining statistical significance were found in the comorbid case-control GWAS: rs4854912 ( $P = 8.9 \times 10^{-8}$ ) and rs13100379 ( $P = 9.7 \times 10^{-8}$ ) within the SRY-Box Transcription Factor 2 Overlapping Transcript (SOX2-OT) gene.

### 3.3.3. BDI with comorbid externalizing disorder

Regarding externalizing disorders, some GWAS on comorbidities in BDI patients have been performed to date. Kerner and colleagues performed two comorbid case-control GWAS assessing substance abuse and alcohol dependence. More specifically, the first GWAS included BDI patients who presented a high probability of endorsing psychotic symptoms and substance abuse (including alcohol) but not dependence. This phenotype was significantly associated with rs1039002 ( $p = 1.7 \times 10^{-8}$ ) located close to the Phosphodiesterase 10A (PDE10A) gene. Suggestive associations with rs12563333 ( $P = 5.9 \times 10^{-8}$ ) and rs13220542 ( $P = 9.0 \times 10^{-8}$ ) were also found. rs12563333 is located upstream of the MAP/Microtubule Affinity-Regulating Kinase 1 (MARK1) gene, and rs13220542 is located downstream of the gene encoding Mitogen-Activated Protein Kinase Kinase Kinase 7 (MAP3K7). The second GWAS included BDI patients with alcohol dependence and substance abuse/dependence. This phenotype was associated with the SNP rs2727943 ( $P = 3.3 \times 10^{-8}$ ) located between the Contactin-4 (CNTN4) and Contactin-6 (CNTN6) genes. Additionally, Kerner and colleagues included a case-control GWAS with a subgroup of BDI patients ( $N = 493$ ) with low probability of comorbidity and a case-control GWAS combining all the patient groups, but no significant associations were observed.

Lydall et al. (2011) performed a comorbid case-control GWAS using BDI patients with alcohol dependence as the case group. However, no marker survived conventional genome-wide significance.

Swaminathan et al. (2015) proposed that BDI patients suffering from alcohol abuse/dependence, drug abuse/dependence, pathological gambling, antisocial personality disorder, attention deficit hyperactivity disorder and conduct disorder could have a common genetic background and thus performed two case-only GWAS to assess their hypothesis. One GWAS compared BDI patients vs. BDI patients with any of the mentioned externalizing disorders, and another GWAS compared BDI patients vs. BDI patients with early onset of such externalizing disorders. However, no SNP attained statistical significance.

## 4. Discussion

Comorbidity in psychiatric patients is difficult to assess following the clinical classification of psychiatric disorders. Researchers are trying to identify genetic variants to help with clinical classification and define patient endophenotypes. There are two ways of approaching this aim. One method is performing GWAS where cases are patients suffering from the two diseases of study, and the second method is performing genetic correlation studies using GWAS data obtained from each disease independently. To the best of our knowledge, the present work is the first systematic review focused on the first type of study and suggests that genes involved in neurotransmission, stress response, neurogenesis and synaptic plasticity may be potentially associated with BDI patients presenting with comorbid conditions.

### 4.1. Migraine

Migraine is a common neurobiological headache disorder caused by increased excitability of the central nervous system (Silberstein, 2004), and its prevalence is greater in BD patients than the general population (Dilsaver et al., 2009). The only associated SNP found in the case-only GWAS of BDI patients with migraine involved the NBEA gene. Although such an association may represent a marker of the BDI plus migraine phenotype or of migraine itself, an analysis performed with migraine GWAS meta-analysis data showed no association of NBEA with migraine (Jacobsen et al., 2015). In addition, the possible role of NBEA in BDI was discarded by the PGC meta-analysis (<http://www.broadinstitute.org/mpg/ricopili/>), which did not show any association between NBEA and BDI. Thus, it is likely that the BDI with comorbid migraine condition represents an independent en-

dophenotype, but information is too limited to make a robust conclusion.

NBEA is a scaffold protein mainly expressed in the brain (Lauks et al., 2012) that is involved in the trafficking of vesicles containing gamma aminobutyric acid (GABA) and glutamate receptors from the post-Golgi site to the cellular membrane (Lauks et al., 2012; Nair et al., 2013). Disturbance of the glutamatergic system is believed to cause cortical spreading depression underlying migraine aura (Cutrer and Smith, 2013; Stuart et al., 2012), and some glutamate-related gene variants are associated with migraine (Anttila et al., 2010; Lighthart et al., 2011). Genetic variants in the glutamate system are also associated with the risk of suffering from BD (Kandaswamy et al., 2014, 2013; Poletti et al., 2015; Sklar et al., 2008). In addition, glutamate levels appear to be altered in BD patients (Ehrlich et al., 2015; Soeiro-de-Souza et al., 2015), and metabotropic glutamate receptors have been proposed as drug targets in some psychiatric condition (Blacker et al., 2017).

#### 4.2. Eating disorders

Eating disorders are a heterogeneous group of psychiatric conditions that usually are associated with dissatisfaction with subject's own body image and implies a perturbation of eating habits. Eating disorders include a broad spectrum of conditions, such as anorexia nervosa, bulimia nervosa and binge eating (Erzegovesi and Bellodi, 2016). Due to the elevated rates of eating disorders among patients with BD (McElroy et al., 2005, 2013) and vice-versa (Fornaro et al., 2020), efforts have been made to find common genetic risk factors underlying both pathologies.

Winham and colleagues performed a GWAS assessing BDI patients with comorbid eating disorders, but they did not find any common genetic marker associated (Winham et al., 2014). Alternatively, Liu and colleagues evaluated samples of BDI patients with comorbid anorexia/bulimia nervosa (Liu et al., 2016) based on the evidence that anorexia and bulimia nervosa share common genetic risk factors (Eckert et al., 1995; Tozzi et al., 2005). In this case, two SNPs in *SOX2-OT* yielded almost statistically significant associations in the comorbid case-control GWAS, suggesting that *SOX2-OT* may be implicated in BDI with comorbid anorexia/bulimia nervosa, BDI or anorexia/bulimia nervosa. However, the absence of an association of *SOX-OT* in the BDI case-control analysis allowed us to exclude its involvement in BDI. On the other hand, prior to this study, a case-control study of anorexia nervosa reported a suggestive association of *SOX2-OT* (Boraska et al., 2014). Thus, available information is not sufficient to determine whether *SOX2-OT* is involved in BDI with comorbid anorexia/bulimia nervosa (and thus it may represent an endophenotype) or rather it is a marker of anorexia nervosa.

*SOX2-OT* is a long non-coding RNA that may regulate the expression of *SOX2* and is involved in embryonic and adult neurogenesis (Amaral et al., 2009) and various cancers (Li et al., 2020).

#### 4.3. Externalizing disorders

Externalizing disorders relates to a group of psychiatric disorders characterized by the presence of disinhibited or externally-focused symptoms, such as impulsivity, aggression, attention problems or delinquent behavior (McElroy et al., 2017). Evidence supports that some externalizing disorders occur in comorbidity with BD, as it is the case of attention deficit hyperactivity disorder (O'Connell et al., 2019), substance abuse (Messer et al., 2017) and alcohol dependence (Di Florio et al., 2014). Within this context, three GWAS have been performed to find genetic markers that could explain the common pathogenesis of patients suffering from both BDI and externalizing disorders.

Kerner and colleagues found that the BDI with comorbid substance abuse phenotype was significantly associated with the *PDE10A*, *MARK1* and *MAP3K7* genes, and the BDI with comorbid alcohol dependence and substance abuse phenotype was significantly associated with the

*CNTN4* and *CNTN6* genes (Kerner et al., 2011). The association of these genes with BDI was not supported by the case-control GWAS performed by Kerner and colleagues, where no statistically significant signal was found. However, we cannot rule out the implication of such genes in alcohol dependence or substance abuse. For instance, given that two intronic SNPs of *CNTN4* have been previously associated with alcohol use (Clark et al., 2015), the associated SNPs may be involved in alcohol dependence rather than in BDI with comorbid alcohol dependence and substance abuse. Therefore, information is not yet sufficient to determine whether BDI with comorbid alcohol dependence and substance abuse phenotype or BDI with substance abuse represent an independent endophenotype.

*PDE10A* is involved in the hydrolysis of the signaling molecules cAMP and cGMP, modulating intracellular signaling pathways. Differential expression of *PDE10A* isoforms in the striatum are present in BDI (Macmullen et al., 2016), and *PDE10A* is genetically associated with BDI (McDonald et al., 2012), which may explain the dysregulation of cAMP signaling observed in BDI (Gaspar et al., 2014). The involvement of *PDE10A* in alcohol abuse is widely accepted (Logrip, 2015; Logrip et al., 2014). Strikingly, Cerbera-Juanes and colleagues found that "low" and "heavy" drinkers presented different methylation patterns in the *PDE10A* gene (Cervera-Juanes et al., 2017).

*MARK1* phosphorylates microtubule-associated proteins and is involved in synaptic plasticity and dendritic trafficking (Drewes et al., 1997), and comorbid nicotine- and alcohol-dependent patients are significantly associated with *MARK1* (Lind et al., 2010).

*MAP3K7* is a serine/threonine protein kinase involved in the cell response to environmental stress (Chen, 2005), and ethanol feeding increases its DNA methylation and protein expression (Khachatoorian et al., 2013).

*CNTN4* and *CNTN6* are both members of a subgroup of the immunoglobulin superfamily. The *CNTN* family of proteins plays an important role in the formation and maintenance of specific neuronal networks in the brain (Yoshihara et al., 1995) as well as in behavioral neurodevelopmental disorders, including alcohol dependence and BDI (Oguro-Ando et al., 2017).

Lydall and colleagues aimed to find genetic markers of the BDI with comorbid alcohol dependence phenotype. However, no SNP attained statistically significant association (Lydall et al., 2011). Also, Swaminazam and colleagues tried to find common genetic markers among a pool of BDI patients with externalizing disorders, but no significance level was reached by any of the SNPs (Swaminathan et al., 2015). Thus, with the available information, it seems that neither BDI with alcohol dependence nor BDI with externalizing disorders patients are likely to define an endophenotype.

## 5. Limitations

The present work has some limitations. First, the main limitation of this review is the small sample size of included papers given that only the BDI case-control GWAS performed by Liu and colleagues approaches the consensually recommended minimum of 2000 cases and 2000 controls (Spencer et al., 2009). The second important limitation is the lack of replication to exclude false positives. This limitation could be explained by the small size of the replication samples, which lack the power to confidently detect genetic variants with small effects. Third, the comorbid condition is occasionally self-reported (Table 1), which may suppose a recall bias. Fourth, in the case of GWAS assessing BDI with comorbid eating disorders and BDI with comorbid anorexia/bulimia nervosa, it is not clear whether people suffering from eating disorders have been excluded from the control group (Liu et al., 2016; Winham et al., 2014), which may interfere with the robustness of the results.

Furthermore, the genetic overlap among psychiatric disorders, and to a less extent, among psychiatric disorders and migraine, a neurological condition, may reflect the existence of common genetic pleiotropic loci conferring risk for multiple psychiatric disorders at a time or rather

the phenotypic overlap between some disorders (Anttila et al., 2018; Smoller et al., 2013). On this basis, we cannot exclude the possibility that the aforementioned associated SNPs may represent risk loci for a shared symptomatology given that BDI and eating disorders also share emotion dysregulation symptoms (McDonald et al., 2019) and BDI, eating disorder and externalizing disorder patients present impulsivity (Beauchaine et al., 2017; Kenny et al., 2019; Najt et al., 2007). Consistently, previous work has noticed the association between BD, impulsivity and the gene Glycogen Synthase Kinase 3 Beta (Jiménez et al., 2014), which is a gene involved in neurogenesis and neuroplasticity.

Finally, apart from a shared genetic background, common environmental triggers cannot be discarded. Childhood maltreatment and physical abuse are precursors of BDI, migraine and eating disorders (Daruy-Filho et al., 2011; Post and Leverich, 2006; Rayworth et al., 2004; Tietjen et al., 2010a, 2010b). Perinatal infection and postnatal stress are risk factors for BDI and alcohol dependence (Tay et al., 2018), and there is an overlap in the epidemiological risk factors for BDI and some externalizing disorders (Mitchell et al., 2019).

## 6. Conclusion

The available literature provides exciting evidence suggesting that genetics may help to diagnose psychiatric disorders. On this basis, clinical features have been used to cluster potential genetically homogenous CDBI patients in GWAS. Unfortunately, due to the reduced number of studies performed to date and their lack of power, the available literature is not yet sufficient to clearly define endophenotypes in BD based on comorbid conditions.

The findings summarized here should therefore be considered as the first step in a pathway leading to the understanding of the pathogenesis behind CDBI and precision psychiatry (Vieta, 2015). Further GWAS with larger samples and more homogenous phenotypes in terms of diagnosis and symptomatology are needed. Furthermore, it would be interesting to study whether the above list of SNPs associated with CDBIs overlaps with the SNPs obtained from genetic correlation studies when available.

Finally, all the above reported genes fall into four different biological pathways: neurogenesis, neurotransmission, synaptic plasticity and stress response. Therefore, we hypothesize that a better understanding of these pathways may help disentangle the genetic complexity behind neuropsychiatric comorbid disorders in BDI patients. In any case, more research is required on functional studies to determine the molecular targets and mechanisms behind the identified genetic variants.

## Declaration of Competing Interest

E. Vieta has received grants and served as consultant, advisor or CME speaker unrelated to this work for the following entities: AB-Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Ferrer, Gedeon Richter, Janssen, Lundbeck, Otsuka, Sage, Sanofi-Aventis, Sunovion, and Takeda. The remaining authors state no conflicts of interest.

## Acknowledgments

The authors have nothing to disclose.

## Author's contributions

Selena Aranda: Conceptualization, investigation and writing original draft. Ester Jiménez, Lourdes Martorell, Gerard Muntané and Eduard Vieta: writing, reviewing and editing the manuscript. Elisabet Vilella: Conceptualization, writing, reviewing and editing the manuscript.

## Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

## Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.jadr.2021.100130.

## References

- Aldinger, F., Schulze, T.G., 2017. Environmental factors, life events, and trauma in the course of bipolar disorder. *Psychiatry Clin. Neurosci.* 71, 6–17. doi:10.1111/pcn.12433.
- Amaral, P.P., Neyt, C., Wilkins, S.J., Askarian-Amiri, M.E., Sunkin, S.M., Perkins, A.C., Mattick, J.S., 2009. Complex architecture and regulated expression of the SOX2OT locus during vertebrate development. *RNA* 15, 2013–2027. doi:10.1261/rna.1705309.
- Anttila, V., Bulik-Sullivan, B., Finucane, H.K., Walters, R.K., Bras, J., Duncan, L., Escott-Price, V., Falcone, G.J., Gormley, P., Malik, R., Patsopoulos, N.A., Ripke, S., Wei, Z., Yu, D., Lee, P.H., Turley, P., Grenier-Boley, B., Chouraki, V., Kamatani, Y., Berr, C., Letenneur, L., Hannequin, D., Amouyel, P., Boland, A., Deleuze, A.F., Duron, E., Vardarajan, B.N., Reitz, C., Goate, A.M., Huettelmann, M.J., Ilyas Kamboh, M., Larson, E.B., Rogaeva, E., George-Hyslop, P.S., Hakonarson, H., Kukull, W.A., Farrer, L.A., Barnes, L.L., Beach, T.G., Yesim Demirci, F., Head, E., Hulette, C.M., Jicha, G.A., Kauwe, J.S.K., Kaye, J.A., Leverenz, J.B., Levey, A.I., Lieberman, A.P., Pankratz, V.S., Poon, W.W., Quinn, J.F., Saykin, A.J., Schneider, L.S., Smith, A.G., Sonnen, J.A., Stern, R.A., Van Deerlin, V.M., Van Eldik, L.J., Harold, D., Russo, G., Rubinsztein, D.C., Bayer, A., Tsolaki, M., Proitsi, P., Fox, N.C., Hampel, H., Owen, M.J., Mead, S., Passmore, P., Morgan, K., Nöthen, M.M., Rossor, M., Lupton, M.K., Hoffmann, P., Kornhuber, J., Lawlor, B., McQuillin, A., Al-Chalabi, A., Bis, J.C., Ruiz, A., Boada, M., Seshadri, S., Beiser, A., Rice, K., Van Der Lee, S.J., De Jager, P.L., Geschwind, D.H., Riemenschneider, M., Riedel-Heller, S., Rotter, J.I., Ransmayr, G., Hyman, B.T., Cruchaga, C., Alegret, M., Winsvold, B., Palta, P., Farh, K.H., Cuenca-Leon, E., Furlotte, N., Kurth, T., Ligthart, L., Terwindt, G.M., Freilinger, T., Ran, C., Gordon, S.D., Borck, G., Adams, H.H.H., Lehtimäki, T., Wedenoja, J., Buring, J.E., Schürks, M., Hrafnisdóttir, M., Hottenga, J.J., Penninx, A., Artto, V., Kaunisto, M., Vepsäläinen, S., Martin, N.G., Montgomery, G.W., Kurki, M.L., Hämäläinen, E., Huang, J., Huang, J., Sandor, C., Webber, C., Muller-Myhsok, B., Schreiber, S., Salomaa, V., Loehrer, E., Göbel, H., Macaya, A., Pozo-Rosich, P., Hansen, T., Werge, T., Kaprio, J., Metspalu, A., Kubisch, C., Ferrari, M.D., Belin, A.C., Van Den Maagdenberg, A.M.J.M., Zwart, J.A., Boomsma, D., Eriksson, N., Olesen, J., Chasman, D.I., Nyholt, D.R., Avbersek, A., Baum, L., Berkovic, S., Bradfield, J., Buono, R., Catarino, C.B., Cossette, P., De Jonghe, P., Depondt, C., Dlugos, D., Ferraro, T.N., French, J., Hjalgrim, H., Jamnadass-Khoda, J., Kälviäinen, R., Kunz, W.S., Lerche, H., Leu, C., Lindhout, D., Lo, W., Lowenstein, D., McCormack, M., Möller, R.S., Molloy, A., Ng, P.W., Oliver, K., Privitera, M., Radtke, R., Ruppert, A.K., Sander, T., Schachter, S., Schankin, C., Scheffer, I., Schoch, S., Sisodiya, S.M., Smith, P., Sperling, M., Striano, P., Surges, R., Neil Thomas, G., Visscher, F., Whelan, C.D., Zera, F., Heinzen, E.L., Marson, A., Becker, F., Stroink, H., Zimprich, F., Gasser, T., Gibbs, R., Heutink, P., Martinez, M., Morris, H.R., Sharma, M., Ryten, M., Mok, K.Y., Pulit, S., Bevan, S., Holliday, E., Attia, J., Battey, T., Boncoraglio, G., Thijs, V., Chen, W.M., Mitchell, B., Rothwell, P., Sharma, P., Sudlow, C., Vicente, A., Markus, H., Kourkoulis, C., Pera, J., Raffeld, M., Silliman, S., Perica, V.B., Thornton, L.M., Huckins, L.M., William Rayner, N., Lewis, C.M., Gratacos, M., Rybakowski, F., Keski-Rahkonen, A., Raevuori, A., Hudson, J.I., Reichborn-Kjennerud, T., Monteleone, P., Karwautz, A., Mannik, K., Baker, J.H., O'Toole, J.K., Trace, S.E., Davis, O.S.P., Helder, S.G., Ehrlich, S., Herpertz-Dahlmann, B., Danner, U.N., Van Elburg, A.A., Clementi, M., Forzan, M., Docampo, E., Lissowska, J., Hauser, J., Tortorella, A., Maj, M., Gonidakis, F., Tziouvas, K., Papezova, H., Yilmaz, Z., Wagner, G., Cohen-Woods, S., Herms, S., Julia, A., Rabionet, R., Dick, D.M., Ripatti, S., Andreassen, O.A., Espeseth, T., Lundervold, A.J., Steen, V.M., Pinto, D., Scherer, S.W., Aschauer, H., Schosser, A., Alfreðsson, L., Padyukov, L., Halmi, K.A., Mitchell, J., Strober, M., Bergen, A.W., Kaye, W., Szatkiewicz, J.P., Cormand, B., Ramos-Quiroga, J.A., Sánchez-Mora, C., Ribasés, M., Casas, M., Hervas, A., Aranz, M.J., Haavik, J., Zayats, T., Johansson, S., Williams, N., Dempfle, A., Rothenberger, A., Kuntsi, J., Oades, R.D., Banaschewski, T., Franke, B., Buitelaar, J.K., Vasquez, A.A., Doyle, A.E., Reif, A., Lesch, K.P., Freitag, C., Rivero, O., Palmason, H., Romanos, M., Langley, K., Rietschel, M., Witt, S.H., Dalsgaard, S., Børglum, A.D., Waldman, I., Wilmot, B., Molly, N., Bau, C.H.D., Crosbie, J., Schachar, R., Loo, S.K., McGough, J.J., Grevet, E.H., Medland, S.E., Robinson, E., Weiss, L.A., Bacchelli, E., Bailey, A., Bal, V., Battaglia, A., Betancur, C., Bolton, P., Cantor, R., Celestino-Soper, P., Dawson, G., De Rubeis, S., Duque, F., Green, A., Klauck, S.M., Leboyer, M., Levitt, P., Maestrini, E., Mane, S., Moreno-De-Luca, D., Parr, J., Regan, R., Reichenberg, A., Sandin, S., Vorstman, J., Wassink, T., Wijsman, E., Cook, E., Santangelo, S., Delorme, R., Roge, B., Magalhaes, T., Arking, D., Schulze, T.G., Thompson, R.C., Strohmaier, J., Matthews, K., Melle, I., Morris, D., Blackwood, D., McIntosh, A., Bergen, S.E., Schalling, M., Jamain, S., Maaser, A., Fischer, S.B., Reinbold, C.S., Fullerton, J.M., Guzman-Parra, J., Mayoral, F., Schofield, P.R., Cichon, S., Mühleisen, T.W., Degenhardt, F., Schumacher, J., Bauer, M., Mitchell, P.B., Gershon, E.S., Rice, J., Potash, J.B., Zandi, P.P., Craddock, N., Nicol Ferrier, I., Alda, M., Rouleau, G.A., Turecki, G., Ophoff, R., Pato, C., Anjorin, A., Stahl, E., Leber, M., Czerski, P.M., Cruceanu, C., Jones, I.R., Posthuma, D., Andlauer, T.F.M., Forstner, A.J., Streit, F., Baune, B.T., Air, T., Sinnamon, G., Wray, N.R., MacIntyre, D.J., Porteous, D., Homuth, G., Rivera, M., Grove, J., Middeldorp, C.M., Hickie, I., Pergadia, M., Mehta, D., Smit, J.H., Jansen, R., De Geus, E., Dunn, E., Li, Q.S., Nauck, M., Schoevers, R.A., Beekman, A.T.F., Knowles, J.A., Viktorin, A., Arnold, P., Barr, C.L., Bedoya-Berrio, G., Joseph Bienvenu, O., Brentani, H., Burton, C., Camarena, B., Capi, C., Cath, D., Cavallini, M., Cusi, D., Darrow, S., Denys, D., Derks, E.M., Dietrich, A., Fernandez, T., Fiege, M., Freimer, N., Gerber, G., Grados, M., Greenberg, E., Hanna, G.L., Hartmann, A., Hirschtritt, M.E., Hoekstra, P.J., Huang, A., Huyser, C., Illmann, C.,

- Jenike, M., Kuperman, S., Iventhal, B., Lochner, C., Lyon, G.J., Macciardi, F., Madruga-Garrido, M., Malaty, L.A., Maras, A., McGrath, L., Miguel, E.C., Mir, P., Nestadt, G., Nicolini, H., Okun, M.S., Pakstis, A., Paschou, P., Piacentini, J., Pittenger, C., Plessen, K., Ramensky, V., Ramos, E.M., Reus, V., Richter, M.A., Riddle, M.A., Robertson, M.M., Roessler, V., Rosário, M., Samuels, J.F., Sandor, P., Stein, D.J., Tsetsos, F., Van Nieuwerburgh, F., Weatherall, S., Wendland, J.R., Wolanczyk, T., Worbe, Y., Zai, G., Goes, F.S., McLaughlin, N., Nestadt, P.S., Grabe, H.J., Depienne, C., Konkashbaev, A., Lanzagorta, N., Valencia-Duarte, A., Bramon, E., Buccola, N., Cahn, W., Cairns, M., Chong, S.A., Cohen, D., Crespo-Facorro, B., Crowley, J., Davidson, M., DeLisi, L., Dinan, T., Donohoe, G., Drapeau, E., Duan, J., Haan, L., Hougaard, D., Karachanak-Yankova, S., Khrunin, A., Klovin, J., Kučinskas, V., Keong, J.L.C., Limborska, S., Loughland, C., Lönnqvist, J., Maher, B., Mattheisen, M., McDonald, C., Murphy, K.C., Nenadic, I., Van Os, J., Pantelis, C., Pato, M., Petryshen, T., Quedest, D., Roussos, P., Sanders, A.R., Schall, U., Schwab, S.G., Sim, K., So, H.C., Stögmanner, E., Subramaniam, M., Toncheva, D., Waddington, J., Walters, J., Weiser, M., Cheng, W., Cloninger, R., Curtis, D., Gejman, P.V., Henskens, F., Mattingsdal, M., Oh, S.Y., Scott, R., Webb, B., Breen, G., Churchhouse, C., Bulik, C.M., Daly, M., Dichgans, M., Faraone, S.V., Guerreiro, R., Holmans, P., Kendler, K.S., Koeleman, B., Mathews, C.A., Price, A., Scharf, J., Sklar, P., Williams, J., Wood, N.W., Cotsapas, C., Palotie, A., Smoller, J.W., Sullivan, P., Rosand, J., Corvin, A., Neale, B.M., 2018. Analysis of shared heritability in common disorders of the brain. *Science* 360 (80). doi:10.1126/science.aap8757.
- Anttila, V., Stefansson, H., Kallela, M., Todt, U., Terwindt, G.M., Calafato, M.S., Nyholt, D.R., Dimas, A.S., Freilinger, T., Müller-Myhsok, B., Arto, V., Inouye, M., Alakurti, K., Kaunisto, M.A., Hämäläinen, E., De Vries, B., Stam, A.H., Weller, C.M., Heinze, A., Heinze-Kuhn, K., Goebel, I., Borck, G., Göbel, H., Steinberg, S., Wolf, C., Björnsson, A., Gudmundsson, G., Kirchmann, M., Hauge, A., Werge, T., Schoonen, J., Eriksson, J.G., Hagen, K., Stovner, L., Wichmann, H.E., Meitinger, T., Alexander, M., Moebus, S., Schreiber, S., Aulchenko, Y.S., Breteler, M.M.B., Uitterlinden, A.G., Hofman, A., Van Duijn, C.M., Tikka-Kleemola, P., Vepsäläinen, S., Lucae, S., Tozzi, F., Muglia, P., Barrett, J., Kaprio, J., Färkkilä, M., Peltonen, L., Stefansson, K., Zwart, J.A., Ferrari, M.D., Olesen, J., Daly, M., Wessman, M., Van Den Maagdenberg, A.M.J.M., Dichgans, M., Kubisch, C., Dermitzakis, E.T., Frants, R.R., Palotie, A., 2010. Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. *Nat. Genet.* 42, 869–873. doi:10.1038/ng.652.
- Beauchaine, T.P., Zisner, A.R., Sauder, C.L., 2017. Trait impulsivity and the externalizing spectrum. *Annu. Rev. Clin. Psychol.* doi:10.1146/annurev-clinpsy-021815-093253.
- Blacker, C.J., Lewis, C.P., Frye, M.A., Veldic, M., 2017. Metabotropic glutamate receptors as emerging research targets in bipolar disorder. *Psychiatry Res.* doi:10.1016/j.psychres.2017.07.059.
- Boraska, V., Franklin, C.S., Floyd, J.A.B., Thornton, L.M., Huckins, L.M., Southam, L., Rayner, N.W., Tachmazidou, I., Klump, K.L., Treasure, J., Lewis, C.M., Schmidt, U., Tozzi, F., Kiezebrink, K., Hebebrand, J., Gorwood, P., Adan, R.A.H., Kas, M.J.H., Favaro, A., Santonastaso, P., Fernández-Aranda, F., Gratacos, M., Rybakowski, F., Dmitrak-Weglarz, M., Kaprio, J., Keski-Rahkonen, A., Raevuori, A., Van Furth, E.F., Slof-Op 't Landt, M.C.T., Hudson, J.I., Reichborn-Kjennerud, T., Knudsen, G.P.S., Monteleone, P., Kaplan, A.S., Karwautz, A., Hakonarson, H., Berrettini, W.H., Guo, Y., Li, D., Schork, N.J., Komaki, G., Ando, T., Inoko, H., Esko, T., Fischer, K., Männik, K., Metspalu, A., Baker, J.H., Cione, R.D., Dackor, J., DeSocio, J.E., Hilliard, C.E., O'Toole, J.K., Pantel, J., Szatkewicz, J.P., Taico, C., Zerwas, S., Trace, S.E., Davis, O.S.P., Helder, S., Bühren, K., Burghardt, R., De Zwaan, M., Egberts, K., Ehrlich, S., Herpertz-Dahlmann, B., Herzog, W., Imgart, H., Scherag, A., Scherag, S., Zipfel, S., Boni, C., Ramoz, N., Versini, A., Brandys, M.K., Danner, U.N., De Kovel, C., Hendriks, J., Koeleman, B.P.C., Ophoff, R.A., Strengman, E., Van Elburg, A.A., Bronson, A., Clementi, M., Degortes, D., Forzan, M., Tenconi, E., Docampo, E., Escaramis, G., Jiménez-Murcia, S., Lissowska, J., Rajewski, A., Szeszenia-Dabrowska, N., Slopian, A., Hauser, J., Karhunen, L., Meulenbelt, I., Slagboom, P.E., Tortorella, A., Maj, M., Dedoussis, G., Dikeos, D., Gonidakis, F., Tziouvas, K., Tsitsika, A., Papezova, H., Slachtova, L., Martaskova, D., Kennedy, J.L., Levitan, R.D., Yilmaz, Z., Huemer, J., Koubek, D., Merl, E., Wagner, G., Lichtenstein, P., Breen, G., Cohen-Woods, S., Farmer, A., McGuffin, P., Cichon, S., Giegling, I., Herms, S., Rujescu, D., Schreiber, S., Wichmann, H.E., Dina, C., Sladec, R., Gambaro, G., Soranzo, N., Julia, A., Marsal, S., Rabionet, R., Gaborieau, V., Dick, D.M., Palotie, A., Ripatti, S., Widén, E., Andreassen, O.A., Espeseth, T., Lundervold, A., Reinvang, I., Steen, V.M., Le Hellard, S., Mattingsdal, M., Ntalla, I., Bencko, V., Foretova, L., Janout, V., Navratilova, M., Gallinger, S., Pinto, D., Scherer, S.W., Aschauer, H., Carlberg, L., Schosser, A., Alfredsson, L., Ding, B., Klareskog, L., Padyukov, L., Courtet, P., Guillaume, S., Jaussent, I., Finan, C., Kalsi, G., Roberts, M., Logan, D.W., Peltonen, L., Ritchie, G.R.S., Barrett, J.C., Anderson, C.A., McGinnis, R., Zeggini, E., Sambrook, J., Stephens, J., Ouwehand, W.H., McArdle, W.L., Ring, S.M., Strachan, D.P., Alexander, G., Bulik, C.M., Collier, D.A., Conlon, P.J., Dominiczak, A., Duncanson, A., Hill, A., Langford, C., Lord, G., Maxwell, A.P., Morgan, L., Sandford, R.N., Sheerin, N., Vannberg, F.O., Blackburn, H., Chen, W.M., Edkins, S., Gillman, M., Gray, E., Hunt, S.E., Onengut-Gumusc, S., Potter, S., Rich, S.S., Simpkin, D., Whittaker, P., Estivill, X., Hinney, A., Sullivan, P.F., 2014. A genome-wide association study of anorexia nervosa. *Mol. Psychiatry* 19, 1085–1094. doi:10.1038/mp.2013.187.
- Carvalho, A.F., Firth, J., Vieta, E., 2020. Bipolar disorder. *N. Engl. J. Med.* 383, 58–66. doi:10.1056/NEJMra1906193.
- Cervera-Juanes, R., Wilhelm, L.J., Park, B., Grant, K.A., Ferguson, B., 2017. Genome-wide analysis of the nucleus accumbens identifies DNA methylation signals differentiating low/binge from heavy alcohol drinking. *Alcohol* 60, 103–113. doi:10.1016/j.alcohol.2016.11.003.
- Chang, C.K., Hayes, R.D., Perera, G., Broadbent, M.T.M., Fernandes, A.C., Lee, W.E., Hotopf, M., Stewart, R., 2011. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. *PLoS One* 6. doi:10.1371/journal.pone.0019590.
- Chen, Z.J., 2005. Ubiquitin signals in the NF-kappaB pathway. *Biochem. Soc. Trans.* 7, 758–765.
- Clark, S.L., Aberg, K.A., Nerella, S., Kumar, G., McClay, J.L., Chen, W., Xie, L.Y., Harada, A., Shabalin, A.A., Gao, G., Bergen, S.E., Hultman, C.M., Magnusson, P.K.E., Sullivan, P.F., van den Oord, E.J.C.G., 2015. Combined whole methylation and genome-wide association study implicates CNTN4 in alcohol use. *Alcohol. Clin. Exp. Res.* 39, 1396–1405. doi:10.1111/acer.12790.
- Cloutier, M., Greene, M., Guerin, A., Touya, M., Wu, E., 2018. The economic burden of bipolar I disorder in the United States in 2015. *J. Affect. Disord.* 226, 45–51. doi:10.1016/j.jad.2017.09.011.
- Crump, C., Sundquist, K., Winkleby, M.A., Sundquist, J., 2013. Comorbidities and mortality in bipolar disorder: a Swedish national cohort study. *JAMA Psychiatry* 70, 931–939. doi:10.1001/jamapsychiatry.2013.1394.
- Cutrer, F.M., Smith, J.H., 2013. Human studies in the pathophysiology of migraine: genetics and functional neuroimaging. *Headache* doi:10.1111/head.12024.
- Dary-Filho, L., Brietzke, E., Lafer, B., Grassi-Oliveira, R., 2011. Childhood maltreatment and clinical outcomes of bipolar disorder. *Acta Psychiatr. Scand.* 124, 427–434. doi:10.1111/j.1600-0447.2011.01756.x.
- Di Florio, A., Craddock, N., van den Bree, M., 2014. Alcohol misuse in bipolar disorder: A systematic review and meta-analysis of comorbidity rates. *Eur. Psychiatry* doi:10.1016/j.eurpsy.2013.07.004.
- Dilsaver, S.C., Benazzi, F., Oedegaard, K.J., Fasmer, O.B., Akiskal, H.S., 2009. Is a family history of bipolar disorder a risk factor for migraine among affectively ill patients? *Psychopathology* 42, 119–123. doi:10.1159/000204762.
- Drewes, G., Ebner, A., Preuss, U., Mandelkow, E.M., Mandelkow, E., 1997. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. *Cell* 89, 297–308. doi:10.1016/S0092-8674(00)80208-1.
- Eckert, E.D., Halmi, K.A., Marchi, P., Grove, W., Crosby, R., 1995. Ten-year follow-up of anorexia nervosa: clinical course and outcome. *Psychol. Med.* 25, 143–156. doi:10.1017/S0033291700028166.
- Ehrlich, A., Schubert, F., Pehrs, C., Gallinat, J., 2015. Alterations of cerebral glutamate in the euthymic state of patients with bipolar disorder. *Psychiatry Res. - Neuroimaging* 233, 73–80. doi:10.1016/j.pscychres.2015.05.010.
- Erzegovesi, S., Bellodi, L., 2016. Eating disorders. *CNS Spectr.* doi:10.1017/S1092852916000304.
- Ferrari, A.J., Stockings, E., Khoo, J.P., Erskine, H.E., Degenhardt, L., Vos, T., Whiteford, H.A., 2016. The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. *Bipolar Disord.* 18, 440–450. doi:10.1111/bdi.12423.
- Fornaro, M., Daray, F.M., Hunter, F., Anastasia, A., Stubbs, B., De Berardis, D., Shin, J.I., Husain, M.I., Dragioti, E., Fusar-Poli, P., Solmi, M., Berk, M., Vieta, E., Carvalho, A.F., 2020. The prevalence, odds and predictors of lifespan comorbid eating disorder among people with a primary diagnosis of bipolar disorders, and vice-versa: systematic review and meta-analysis. *J. Affect. Disord.* 280, 409–431. doi:10.1016/j.jad.2020.11.015.
- Gaspar, L., van de Werken, M., Johansson, A.S., Moriggi, E., Owe-Larsson, B., Kocks, J.W.H., Lundkvist, G.B., Gordijn, M.C.M., Brown, S.A., 2014. Human cellular differences in cAMP – CREB signaling correlate with light-dependent melatonin suppression and bipolar disorder. *Eur. J. Neurosci.* 40, 2206–2215. doi:10.1111/ejn.12602.
- Goes, F.S., 2015. The importance of anxiety states in bipolar disorder. *Curr. Psychiatry Rep.* doi:10.1007/s11920-014-0540-2.
- Gordovez, F.J.A., McMahon, F.J., 2020. The genetics of bipolar disorder. *Mol. Psychiatry* doi:10.1038/s41380-019-0634-7.
- Grande, I., Berk, M., Birmaher, B., Vieta, E., 2016. Bipolar disorder. *Lancet* doi:10.1016/S0140-6736(15)00241-X.
- Hirschfeld, R.M., Vornik, L.A., 2005. Bipolar disorder-cost and comorbidity. *Am. J. Manag. Care* 11, S85–S90.
- Jacobsen, K.K., Nievergelt, C.M., Zayats, T., Greenwood, T.A., Anttila, V., Akiskal, H.S., Haavik, J., Bernt Fasmer, O., Kelsø, J.R., Johansson, S., Oedegaard, K.J., 2015. Genome wide association study identifies variants in NBEA associated with migraine in bipolar disorder. *J. Affect. Disord.* 172, 453–461. doi:10.1016/j.jad.2014.10.004.
- Jiménez, E., Arias, B., Mitjans, M., Goikolea, J.M., Roda, E., Ruiz, V., Pérez, A., Sáiz, P.A., Paz García-Portilla, M., Burón, P., Bobes, J., Vieta, E., Benabarre, A., 2014. Association between GSK3β gene and increased impulsivity in bipolar disorder. *Eur. Neuropsychopharmacol.* 24, 510–518. doi:10.1016/j.euroneuro.2014.01.005.
- Judd, L.L., Schettler, P.J., Solomon, D.A., Maser, J.D., Coryell, W., Endicott, J., Akiskal, H.S., 2008. Psychosocial disability and work role function compared across the long-term course of bipolar I, bipolar II and unipolar major depressive disorders. *J. Affect. Disord.* 108, 49–58. doi:10.1016/j.jad.2007.06.014.
- Kandaswamy, R., McQuillin, A., Curtis, D., Gurling, H., 2014. Allelic association, DNA resequencing and copy number variation at the metabotropic glutamate receptor GRM7 gene locus in bipolar disorder. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* 165, 365–372. doi:10.1002/ajmg.b.32239.
- Kandaswamy, R., McQuillin, A., Sharp, S.I., Fiorentino, A., Anjorin, A., Blizard, R.A., Curtis, D., Gurling, H.M.D., 2013. Genetic association, mutation screening and functional analysis of a Kozak sequence variant in the metabotropic glutamate receptor 3 gene in bipolar disorder. *JAMA Psychiatry* 70, 591–598. doi:10.1001/jamapsychiatry.2013.38.
- Kenny, T.E., Singleton, C., Carter, J.C., 2019. An examination of emotion-related facets of impulsivity in binge eating disorder. *Eat. Behav.* 32, 74–77. doi:10.1016/j.eatbeh.2018.12.006.
- Kerner, B., Brugman, D.L., Freimer, N.B., 2007. Evidence of linkage to psychosis on chromosome 5q33-34 in pedigrees ascertained for bipolar disorder. *Am. J. Med. Genet. Part B Neuropsychiatr. Genet.* 144, 74–78. doi:10.1002/ajmg.b.30402.
- Kerner, B., Lambert, C.G., Muthén, B.O., 2011. Genome-wide association study in

- bipolar patients stratified by co-morbidity. *PLoS One* 6, 1–10. doi:10.1371/journal.pone.0028477.
- Khachatoorian, R., Dawson, D., Maloney, E.M., Wang, J., French, B.A., French, S.W., French, S.W., 2013. SAME treatment prevents the ethanol-induced epigenetic alterations of genes in the toll-like receptor pathway. *Exp. Mol. Pathol.* 94, 243–246. doi:10.1016/j.yexmp.2012.09.024.SAME.
- Lauks, J., Klemmer, P., Farzana, F., Karupothula, R., Zalm, R., Cooke, N.E., Li, K.W., Smit, A.B., Toonen, R., Verhage, M., 2012. Synapse associated protein 102 (SAP102) binds the C-terminal part of the scaffolding protein neurobeachin. *PLoS One* 7. doi:10.1371/journal.pone.0039420.
- Li, Y., Du, M., Wang, S., Zha, J., Lei, P., Wang, X., Wu, D., Zhang, J., Chen, D., Huang, D., Lu, J., Li, H., Sun, M., 2020. Clinicopathological implication of long non-coding RNAs SOX2 overlapping transcript and its potential target gene network in various cancers. *Front. Genet.* doi:10.3389/fgene.2019.01375.
- Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P.A., Clarke, M., Devereaux, P.J., Kleijnen, J., Moher, D., 2009. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *PLoS Med.* 6. doi:10.1371/journal.pmed.1000100.
- Ligthart, L., De Vries, B., Smith, A.V., Ikram, M.A., Amin, N., Hottenga, J.J., Koellewijn, S.C., Kattenberg, V.M., De Moor, M.H.M., Janssens, A.C.J.W., Aulchenko, Y.S., Oostra, B.A., De Geus, E.J.C., Smit, J.H., Zitman, F.G., Uitterlinden, A.G., Hofman, A., Willemssen, G., Nyholt, D.R., Montgomery, G.W., Terwindt, G.M., Gudnason, V., Penninx, B.W.J.H., Breteler, M., Ferrari, M.D., Launer, L.J., Van Duijn, C.M., Van Den Maagdenberg, A.M.J.M., Boomsma, D.I., 2011. Meta-analysis of genome-wide association for migraine in six population-based European cohorts. *Eur. J. Hum. Genet.* 19, 901–907. doi:10.1038/ejhg.2011.48.
- Lind, P.A., Macgregor, S., Vink, J.M., Pergadia, M.L., Hansell, N.K., Moor, M.H.M., Smit, A.B., Hottenga, J., Richter, M., Heath, A.C., Martin, N.G., Willemssen, G., Geus, E.J.C., De, Vogelzangs, N., Penninx, B.W., Whitfield, J.B., Montgomery, G.W., Boomsma, D.I., Madden, P.A.F., 2010. A Genome Wide Association Study of Nicotine and Alcohol Dependence in Australian and Dutch Populations 13, 10–29. <https://doi.org/10.1375/twin.13.1.10.A>.
- Liu, X., Kelsø, J.R., Greenwood, T.A., Kelsø, J.R., Green-Wood, T.A., Nievergelt, C.M., McKinney, R., Shilling, P.D., Smith, E.N., Schork, N.J., Bloss, C.S., Nurnberger, J.I., Edenberg, H.J., Foroud, T., Koller, D.L., Gershon, E.S., Liu, C., Badner, J.A., Scheftner, W.A., Lawson, W.B., Nwulia, E.A., Hipolito, M., Coryell, W., Potash, J.B., Rice, J., Byerley, W., McMahon, F.J., Schulze, T.G., Berrettini, W.H., Zandi, P.P., Mahon, P.B., McInnis, M.G., Zöllner, S., Zhang, P., Craig, D.W., Szelinger, S., Barrett, T.B., 2016. A genome-wide association study of bipolar disorder with comorbid eating disorder replicates the SOX2-OT region. *J. Affect. Disord.* 189, 141–149. doi:10.1016/j.jad.2015.09.029.
- Logrip, M.L., 2015. Phosphodiesterase regulation of alcohol drinking in rodents. *Alcohol. Clin. Exp. Res.* 49, 795–802. doi:10.1016/j.physbeh.2017.03.040.
- Logrip, M.L., Vendruscolo, L.F., Schlosburg, J.E., Koob, G.F., Zorrilla, E.P., 2014. Phosphodiesterase 10A regulates alcohol and saccharin self-administration in rats. *Neuropsychopharmacology* 39, 1722–1731. doi:10.1038/npp.2014.20.
- Lydall, G.J., Bass, N.J., McQuillin, A., Lawrence, J., Anjorin, A., Kandaswamy, R., Pereira, A., Guerrini, I., Curtis, D., Vine, A.E., Sklar, P., Purcell, S.M., Gurling, H.M.D., 2011. Confirmation of prior evidence of genetic susceptibility to alcoholism in a genome-wide association study of comorbid alcoholism and bipolar disorder. *Psychiatr.* 21, 294–306. doi:10.1097/YPG.0b013e32834915c2.
- Macmullen, C.M., Vick, K., Pacifico, R., Fallahi-Sichani, M., Davis, R.L., 2016. Novel, primate-specific PDE10A isoform highlights gene expression complexity in human striatum with implications on the molecular pathology of bipolar disorder. *Transl. Psychiatry* 6, 1–9. doi:10.1038/tp.2016.3.
- McDonald, C.E., Rossell, S.L., Phillipou, A., 2019. The comorbidity of eating disorders in bipolar disorder and associated clinical correlates characterised by emotion dysregulation and impulsivity: a systematic review. *J. Affect. Disord.* doi:10.1016/j.jad.2019.08.070.
- McDonald, M.L., MacMullen, C., Liu, D.J., Leal, S.M., Davis, R.L., 2012. Genetic association of cyclic AMP signaling genes with bipolar disorder. *Transl. Psychiatry* 2, e169. doi:10.1038/tp.2012.92, 10.
- McElroy, E., Shevlin, M., Murphy, J., 2017. Internalizing and externalizing disorders in childhood and adolescence: a latent transition analysis using ALSPAC data. *Compr. Psychiatry* 75, 75–84. doi:10.1016/j.comppsy.2017.03.003.
- McElroy, S.L., 2004. Diagnosing and treating comorbid (complicated) bipolar disorder. *J. Clin. Psychiatry* 65, 35–44.
- McElroy, S.L., Crow, S., Biernacka, J.M., Winham, S., Geske, J., Barboza, A.B.C., Prieto, M.L., Chauhan, M., Seymour, L.R., Mori, N., Frye, M.A., 2013. Clinical phenotype of bipolar disorder with comorbid binge eating disorder. *J. Affect. Disord.* 150, 981–986. doi:10.1016/j.jad.2013.05.024.
- McElroy, S.L., Kotwal, R., Keck, P.E., Akiskal, H.S., 2005. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? *J. Affect. Disord.* doi:10.1016/j.jad.2004.11.008.
- McIntyre, R.S., Berk, M., Brietzke, E., Goldstein, B.I., López-Jaramillo, C., Kessing, L.V., Malhi, G.S., Nierenberg, A.A., Rosenblatt, J.D., Majeed, A., Vieta, E., Vinberg, M., Young, A.H., Mansur, R.B., 2020. Bipolar disorders. *Lancet* doi:10.1016/S0140-6736(20)31544-0.
- McIntyre, R.S., Konarski, J.Z., Yatham, L.N., 2004. Comorbidity in bipolar disorder: a framework for rational treatment selection. *Hum. Psychopharmacol.* doi:10.1002/hup.612.
- McIntyre, R.S., Nguyen, H.T., Soczynska, J.K., Lourenco, M.T.C., Woldeyohannes, H.O., Konarski, J.Z., 2008. Medical and substance-related comorbidity in bipolar disorder: translational research and treatment opportunities. *Dialogues Clin. Neurosci.* 10, 203–213.
- Messer, T., Lammerts, G., Müller-Siecheneder, F., Schmidt, R.F., Latifi, S., 2017. Substance abuse in patients with bipolar disorder: a systematic review and meta-analysis. *Psychiatry Res* doi:10.1016/j.psychres.2017.02.067.
- Mitchell, B.L., Campos, A.I., Rentería, M.E., Parker, R., Sullivan, L., Mcaloney, K., Couvy-Duchesne, B., Medland, S.E., Gillespie, N.A., Scott, J., Zietsch, B.P., Lind, P.A., Martin, N.G., Hickie, I.B., 2019. Twenty-five and up (25up) study: a new wave of the Brisbane longitudinal twin study. *Twin Res. Hum. Genet.* 22, 154–163. doi:10.1017/thg.2019.27.
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Altman, D., Antes, G., Atkins, D., Barbour, V., Barrowman, N., Berlin, J.A., Clark, J., Clarke, M., Cook, D., D'Amico, R., Deeks, J.J., Devereaux, P.J., Dickersin, K., Egger, M., Ernst, E., Gøtzsche, P.C., Grimshaw, J., Guyatt, G., Higgins, J., Ioannidis, J.P.A., Kleijnen, J., Lang, T., Magrini, N., McNamee, D., Moja, L., Mulrow, C., Napoli, M., Oxman, A., Pham, B., Rennie, D., Sampson, M., Schulz, K.F., Shekelle, P.G., Tovey, D., Tugwell, P., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med.* doi:10.1371/journal.pmed.1000097.
- Nair, R., Lauks, J., Jung, S.Y., Cooke, N.E., de Wit, H., Brose, N., Kilimann, M.W., Verhage, M., Rhee, J.S., 2013. Neurobeachin regulates neurotransmitter receptor trafficking to synapses. *J. Cell Biol.* 200, 61–80. doi:10.1083/jcb.201207113.
- Najt, P., Perez, J., Sanches, M., Peluso, M.A.M., Glahn, D., Soares, J.C., 2007. Impulsivity and bipolar disorder. *Eur. Neuropsychopharmacol.* doi:10.1016/j.euroneuro.2006.10.002.
- O'Connell, K.S., Shadrin, A., Bahrami, S., Smeland, O.B., Bettella, F., Frei, O., Krull, F., Askeland, R.B., Walters, G.B., Davíðsdóttir, K., Haraldsdóttir, G.S., Guðmundsson, Ó., Stefánsson, H., Fan, C.C., Steen, N.E., Reichborn-Kjennerud, T., Dale, A.M., Stefánsson, K., Djurovic, S., Andreassen, O.A., 2019. Identification of genetic overlap and novel risk loci for attention-deficit/hyperactivity disorder and bipolar disorder. *Mol. Psychiatry* doi:10.1038/s41380-019-0613-z.
- Oguro-Ando, A., Zuko, A., Kleijer, K.T., Burbach, J.P.H., 2017. A current view on contactin-4, -5 and -6: implications in neurodevelopmental disorders. *Mol. Cell. Neurosci.* 81, 72–83.
- Poletti, S., Locatelli, C., Pirovano, A., Colombo, C., Benedetti, F., 2015. Glutamate EAAT1 transporter genetic variants influence cognitive deficits in bipolar disorder. *Psychiatry Res.* 226, 407–408. doi:10.1016/j.psychres.2014.12.071.
- Popovic, D., Vieta, E., Azorin, J.M., Angst, J., Bowden, C.L., Mosolov, S., Young, A.H., Perugi, G., 2015. Suicide attempts in major depressive episode: evidence from the BRIDGE-II-Mix study. *Bipolar Disord.* 17, 795–803. doi:10.1111/bdi.12338.
- Post, R.M., Leverich, G.S., 2006. The role of psychosocial stress in the onset and progression of bipolar disorder and its comorbidities: the need for earlier and alternative modes of therapeutic intervention. *Dev. Psychopathol.* 18, 1181–1211. doi:10.1017/S0954579406060573.
- Potash, J.B., Toolan, J., Steele, J., Miller, E.B., Pearl, J., Zandi, P.P., Schulze, T.G., Kassem, L., Simpson, S.G., Lopez, V., MacKinnon, D.F., McMahon, F.J., 2007. The bipolar disorder phenotype database: a resource for genetic studies. *Am. J. Psychiatry* 164, 1229–1237. doi:10.1176/appi.ajp.2007.06122045.
- Rayworth, B.B., Wise, L.A., Harlow, B.L., 2004. Childhood abuse and risk of eating disorders in women. *Epidemiology* 15, 271–278. doi:10.1097/01.ede.0000120047.07140.9d.
- Samamé, C., 2013. Social cognition throughout the three phases of bipolar disorder: a state-of-the-art overview. *Psychiatry Res.* doi:10.1016/j.psychres.2013.08.012.
- Silberstein, S.D., 2004. Migraine. In: *Lancet*. Elsevier Limited, pp. 381–391. doi:10.1016/S0140-6736(04)15440-8.
- Sklar, P., Smoller, J.W., Fan, J., Ferreira, M.A.R., Perlis, R.H., Chambert, K., Nimgaonkar, V.L., McQueen, M.B., Faraone, S.V., Kirby, A., De Bakker, P.I.W., Ogdie, M.N., Thase, M.E., Sachs, G.S., Todd-Brown, K., Gabriel, S.B., Sougnez, C., Gates, C., Blumenstiel, B., Defelice, M., Ardlie, K.G., Franklin, J., Muir, W.J., McGhee, K.A., MacIntyre, D.J., McLean, A., VanBeck, M., McQuillin, A., Bass, N.J., Robinson, M., Lawrence, J., Anjorin, A., Curtis, D., Scolnick, E.M., Daly, M.J., Blackwood, D.H., Gurling, H.M., Purcell, S.M., 2008. Whole-genome association study of bipolar disorder. *Mol. Psychiatry* 13, 558–569. doi:10.1038/sj.mp.4002151.
- Smoller, J.W., Kendler, K., Craddock, N., Lee, P.H., Neale, B.M., Nurnberger, J.N., Ripke, S., Santangelo, S., Sullivan, P.S., Neale, B.N., Purcell, S., Anney, R., Buitelaar, J., Fanous, A., Faraone, S.F., Hoogendijk, W., Lesch, K.P., Levinson, D.L., Perlis, R.P., Rietschel, M., Riley, B., Sonuga-Barke, E., Schachar, R., Schulze, T.S., Thapar, A., Kendler, K.K., Smoller, J.S., Neale, M., Perlis, R., Bender, P., Cichon, S., Daly, M.D., Kelsø, J., Lehner, T., Levinson, D., O'Donovan, M., Gejman, P., Sebat, J., Sklar, P., Daly, M., Devlin, B., Sullivan, P., O'Donovan, M., Michael, 2013. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* 381, 1371–1379. doi:10.1016/S0140-6736(12)62129-1.
- Soeiro-de-Souza, M.G., Henning, A., Machado-Vieira, R., Moreno, R.A., Pastorello, B.F., da Costa Leite, C., Vallada, H., Otaduy, M.C.G., 2015. Anterior cingulate Glutamate-Glutamine cycle metabolites are altered in euthymic bipolar I disorder. *Eur. Neuropsychopharmacol.* 25, 2221–2229. doi:10.1016/j.euroneuro.2015.09.020.
- Solé, B., Jiménez, E., Torrent, C., del Mar Bonnin, C., Torres, I., Reinares, M., Priego, Á., Salamero, M., Colom, F., Varo, C., Vieta, E., Martínez-Arán, A., 2016. Cognitive variability in bipolar II disorder: WHO is cognitively impaired and who is preserved. *Bipolar Disord.* 18, 288–299. doi:10.1111/bdi.12385.
- Spencer, C.C.A., Su, Z., Donnelly, P., Marchini, J., 2009. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. *PLoS Genet.* 5, e1000477. doi:10.1371/journal.pgen.1000477.
- Stahl, E.A., Breen, G., Forstner, A.J., McQuillin, A., Ripke, S., Trubetskoy, V., Mattheisen, M., Wang, Y., Coleman, J.R.I., Gaspar, H.A., de Leeuw, C.A., Steinberg, S., Pavlides, J.M.W., Trzaskowski, M., Byrne, E.M., Pers, T.H., Holmans, P.A., Richards, A.L., Abbott, L., Agerbo, E., Akil, H., Albani, D., Alliey-Rodriguez, N., Als, T.D., Anjorin, A., Antilla, V., Awasthi, S., Badner, J.A., Bækvad-Hansen, M., Barchas, J.D., Bass, N., Bauer, M., Belliveau, R., Bergen, S.E., Pedersen, C.B.,

- Bøen, E., Boks, M.P., Boocock, J., Budde, M., Bunney, W., Burmeister, M., Bybjerg-Grauholm, J., Byerley, W., Casas, M., Cerrato, F., Cervantes, P., Chambert, K., Charney, A.W., Chen, D., Churchhouse, C., Clarke, T.K., Coryell, W., Craig, D.W., Cruceanu, C., Curtis, D., Czerski, P.M., Dale, A.M., de Jong, S., Degenhardt, F., DeLaverio, J., DePaulo, J.R., Djurovic, S., Dobbyn, A.L., Dumont, A., Elvsåshagen, T., Escott-Price, V., Fan, C.C., Fischer, S.B., Flickinger, M., Foroud, T.M., Forty, L., Frank, J., Fraser, C., Freimer, N.B., Frisén, L., Gade, K., Gage, D., Garnham, J., Gímbartolomei, C., Pedersen, M.G., Goldstein, J., Gordon, S.D., Gordon-Smith, K., Green, E.K., Green, M.J., Greenwood, T.A., Grove, J., Guan, W., Guzman-Parra, J., Hamshere, M.L., Hautzinger, M., Heilbronner, U., Herms, S., Hipolito, M., Hoffmann, P., Holland, D., Huckins, L., Jamain, S., Johnson, J.S., Juréus, A., Kandawamy, R., Karlsson, R., Kennedy, J.L., Kittel-Schneider, S., Knowles, J.A., Kogevinas, M., Koller, A.C., Kupka, R., Lavebratt, C., Lawrence, J., Lawson, W.B., Leber, M., Lee, P.H., Levy, S.E., Li, J.Z., Liu, C., Lucae, S., Maaser, A., MacIntyre, D.J., Mahon, P.B., Maier, W., Martinsson, L., McCarroll, S., McGuffin, P., McInnis, M.G., McKay, J.D., Medeiros, H., Medland, S.E., Meng, F., Milani, L., Montgomery, G.W., Morris, D.W., Mühlisen, T.W., Mullins, N., Nguyen, H., Nievergelt, C.M., Adolfsson, A.N., Nwulia, E.A., O'Donovan, C., Loohuis, L.M.O., Ori, A.P.S., Oruc, L., Ösby, U., Perlis, R.H., Perry, A., Pfennig, A., Potash, J.B., Purcell, S.M., Regeer, E.J., Reif, A., Reinbold, C.S., Rice, J.P., Rivas, F., Rivera, M., Roussos, P., Ruderfer, D.M., Ryu, E., Sánchez-Mora, C., Schatzberg, A.F., Scheftner, W.A., Schork, N.J., Shannon Weickert, C., Shekhtman, T., Shilling, P.D., Sigurdsson, E., Slaney, C., Smeland, O.B., Sobell, J.L., Søholm Hansen, C., Spjiker, A.T., St Clair, D., Steffens, M., Strauss, J.S., Streit, F., Strohmaier, J., Szelinger, S., Thompson, R.C., Thorgeirsson, T.E., Treutlein, J., Vedder, H., Wang, W., Watson, S.J., Weickert, T.W., Witt, S.H., Xi, S., Xu, W., Young, A.H., Zandi, P., Zhang, P., Zöllner, S., Adolfsson, R., Agartz, I., Alda, M., Backlund, L., Baune, B.T., Bellivier, F., Berrettini, W.H., Biernacka, J.M., Blackwood, D.H.R., Boehnke, M., Børglum, A.D., Corvin, A., Craddock, N., Daly, M.J., Dannlowski, U., Esko, T., Etain, B., Frye, M., Fullerton, J.M., Gershon, E.S., Gill, M., Goes, F., Grigoriou-Serbanescu, M., Hauser, J., Hougaard, D.M., Hultman, C.M., Jones, I., Jones, L.A., Kahn, R.S., Kirov, G., Landén, M., Leboyer, M., Lewis, C.M., Li, Q.S., Lissowska, J., Martin, N.G., Mayoral, F., McElroy, S.L., McIntosh, A.M., McMahon, F.J., Melle, I., Metspalu, A., Mitchell, P.B., Morken, G., Mors, O., Mortensen, P.B., Müller-Myhsok, B., Myers, R.M., Neale, B.M., Nimgaonkar, V., Nordentoft, M., Nöthen, M.M., O'Donovan, M.C., Oedegaard, K.J., Owen, M.J., Paciga, S.A., Pato, C., Pato, M.T., Posthuma, D., Ramos-Quiroga, J.A., Ribasés, M., Rietschel, M., Rouleau, G.A., Schalling, M., Schofield, P.R., Schulze, T.G., Serretti, A., Smoller, J.W., Stefansson, H., Stefansson, K., Stordal, E., Sullivan, P.F., Turecki, G., Vaaler, A.E., Vieta, E., Vincent, J.B., Werge, T., Nurnberger, J.I., Wray, N.R., Di Florio, A., Edenberg, H.J., Cichon, S., Ophoff, R.A., Scott, L.J., Andreassen, O.A., Kelsoe, J., Sklar, P., 2019. Genome-wide association study identifies 30 loci associated with bipolar disorder. *Nat. Genet.* 51, 793–803. doi:10.1038/s41588-019-0397-8.
- Stuart, S., Cox, H.C., Lea, R.A., Griffiths, L.R., 2012. The Role of the MTHFR Gene in Migraine.
- Swaminathan, S., Koller, D.L., Foroud, T., Edenberg, H.J., Xuei, X., Niculescu, A.B., Bipolar Genome Study (BiGS) Consortium, Nurnberger, J.I., 2015. Characteristics of bipolar I patients grouped by externalizing disorders. *J. Affect. Disord.* 178, 206–214. doi:10.1016/j.jphysbeh.2017.03.040.
- Sylvia, L.G., Shelton, R.C., Kemp, D.E., Bernstein, E.E., Friedman, E.S., Brody, B.D., Mcelroy, S.L., Singh, V., Tohen, M., Bowden, C.L., Ketter, T.A., Deckersbach, T., Thase, M.E., Reilly-Harrington, N.A., Nierenberg, A.A., Rabideau, D.J., Kinrys, G., Kocsis, J.H., Bobo, W.V., Kamali, M., McInnis, M.G., Calabrese, J.R., 2015. Medical burden in bipolar disorder: findings from the Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE). *Bipolar Disord.* 17, 212–223. doi:10.1111/bdi.12243.
- Tay, T.L., Béchade, C., D'Andrea, I., St-Pierre, M.K., Henry, M.S., Roumier, A., Tremblay, M.E., 2018. Microglia gone rogue: impacts on psychiatric disorders across the lifespan. *Front. Mol. Neurosci.* 10, 1–26. doi:10.3389/fnmol.2017.00421.
- Tietjen, G.E., Brandes, J.L., Peterlin, B.L., Eloff, A., Dafer, R.M., Stein, M.R., Drexler, E., Martin, V.T., Hutchinson, S., Aurora, S.K., Recober, A., Herial, N.A., Utley, C., White, L., Khuder, S.A., 2010a. Childhood maltreatment and migraine (Part I). Prevalence and adult revictimization: a multicenter headache clinic survey. *Headache J. Head Face Pain* 50, 20–31. doi:10.1111/j.1526-4610.2009.01556.x.
- Tietjen, G.E., Brandes, J.L., Peterlin, B.L., Eloff, A., Dafer, R.M., Stein, M.R., Drexler, E., Martin, V.T., Hutchinson, S., Aurora, S.K., Recober, A., Herial, N.A., Utley, C., White, L., Khuder, S.A., 2010b. Childhood maltreatment and migraine (Part II). Emotional abuse as a risk factor for headache chronification. *Headache J. Head Face Pain* 50, 32–41. doi:10.1111/j.1526-4610.2009.01557.x.
- Tozzi, F., Thornton, L.M., Klump, K.L., Fichter, M.M., Halmi, K.A., Kaplan, A.S., Strober, M., Woodside, D.B., Crow, S., Mitchell, J., Rotondo, A., Mauri, M., Casano, G., Keel, P., Plotnicov, K.H., Pollice, C., Lilienfeld, L.R., Berrettini, W.H., Bulik, C.M., Kaye, W.H., 2005. Symptom fluctuation in eating disorders: correlates of diagnostic crossover. *Am. J. Psychiatry* 162, 732–740. doi:10.1176/appi.ajp.162.4.732.
- Vieta, E., 2015. Personalised medicine applied to mental health: precision psychiatry. *Rev. Psiquiatr. Salud Ment.* 8, 117–118. doi:10.1016/j.rpsm.2015.03.003.
- Vieta, E., Colom, F., Corbella, B., Martínez-Ará, A., Reinares, M., Benabarre, A., Bal Gastó, C., 2001. Clinical correlates of psychiatric comorbidity in bipolar I patients. *Bipolar Disord.* 3, 253–258.
- Wagner, K.D., Dineen Wagner, K., 2004. Diagnosis and treatment of bipolar disorder in children and adolescents. *J. Clin. Psychiatry Suppl.* 65, 30–34.
- Winham, S.J., Cuellar-Barboza, A.B., McElroy, S.L., Oliveros, A., Crow, S., Colby, C.L., Choi, D.S., Chauhan, M., Frye, M.A., Biernacka, J.M., 2014. Bipolar disorder with comorbid binge eating history: a genome-wide association study implicates APOB. *J. Affect. Disord.* 165, 151–158. doi:10.1016/j.jad.2014.04.026.
- Yoshihara, Y., Kawasaki, M., Tamada, A., Nagata, S., Kagamiyama, H., Mori, K., 1995. Overlapping and differential expression of BIG-2, BIG-1, TAG-1, and F3: four members of an axon-associated cell adhesion molecule subgroup of the immunoglobulin superfamily. *J. Neurobiol.* 28, 51–69. doi:10.1002/neu.480280106.